(R) -Pirtobrutinib
(R) -Pirtobrutinib ((R) -LOXO-305) is a less active enantiomer of Pirtobrutinib. Pirtobrutinib (LOXO-305), a highly selective and non-covalent next generation BTK inhibitor, inhibits diverse BTK C481 substitution mutations[1].
Product Specifications
CAS Number
2101700-14-3
Product Name Alternative
(R) -LOXO-305
UNSPSC
12352005
Target
Btk
Type
Reference compound
Related Pathways
Protein Tyrosine Kinase/RTK
Field of Research
Others
Assay Protocol
https://www.medchemexpress.com/r-pirtobrutinib.html
Concentration
10mM
Purity
99.78
Solubility
DMSO : 200 mg/mL (ultrasonic)
Smiles
O=C(C1=C(N)N([C@H](C)C(F)(F)F)N=C1C2=CC=C(CNC(C3=CC(F)=CC=C3OC)=O)C=C2)N
Molecular Formula
C22H21F4N5O3
Molecular Weight
479.43
References & Citations
[1]Gomez E B , et al. Loxo-305, a Highly Selective and Non-Covalent Next Generation BTK Inhibitor, Inhibits Diverse BTK C481 Substitution Mutations[J]. Blood, 2019, 134 (Supplement_1) :4644-4644.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
BNC402853-100 1x 100 µL
CD54 / ICAM-1 (15.2), CF640R conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
BNC402823-100 1x 100 µL
BMI1 (Oncogene and Stem Cell Marker) (BMI1/2823), CF640R conjugate, 0.1mg/mL
Sign In for Pricing
View Details